I. Determine the time to progression in patients treated with this regimen. II. Determine
the survival duration of patients treated with this regimen. III. Determine the toxicity of
this regimen in these patients. IV. Correlate the expression of epidermal growth factor
receptor and cyclooxygenase-2 in tumor specimens with response, time to progression, and
survival in patients treated with this regimen.

Name

Location

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.